About BiosLab
BiosLab is a company based in India. The company has 57 employees. BiosLab offers products and services including BIOTENLY ® Teneligliptin and TELEXA ® Telmisartan.
- Headquarter India
- Employees 57
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Legal Name Bios Lab Pvt. Ltd
- Date of Incorporation 10 Apr, 2015
- Jurisdiction Rajkot, Gujarat, India
- Annual Revenue₹14.19 Cr
FY 2025 · +10% YoY
- Net Profit₹57.5 Lakh
FY 2025 · 4% margin
- EBITDA₹1.04 Cr
FY 2025 · 7% margin
- Employee Count57
Associated legal entities of BiosLab
BiosLab operates through Bios Lab Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bios Lab Private Limited CIN U24230GJ2015PTC082869 | Active | 10 Apr 2015 | Rajkot, Gujarat | ₹14.2 Cr | 57 | 3 | View details |
Products & Services of BiosLab
BiosLab offers a comprehensive portfolio of products and services, including BIOTENLY ® Teneligliptin and TELEXA ® Telmisartan.
This product is developed for diabetes management and is manufactured under strict quality controls to ensure effective pharmacological action.
This product is formulated for hypertension treatment and is produced with advanced facilities to guarantee optimal quality and efficacy.
Board of directors of Bios Lab Private Limited (BiosLab)
Bios Lab Private Limited is the primary company behind BiosLab. The board of Bios Lab Private Limited currently have 3 directors; the longest-serving is Sachin Navnitbhai Shishangiya, appointed in 2015.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sachin Navnitbhai Shishangiya DIN 07107058 | Director | 10 Apr 2015 | 11 yrs 6 mo | Bios Lab Private Limited |
| Bharat Ramjibhai Solanki DIN 06875678 | Director | 10 Apr 2015 | 11 yrs 6 mo | Bios Lab Private Limited |
| Sandip Navnitbhai Shishangia DIN 07109010 | Director | 10 Apr 2015 | 11 yrs 6 mo | Bios Lab Private Limited |
Financials of BiosLab
Figures of Bios Lab Private Limited, the primary company behind BiosLab, for FY 2025. Revenue was ₹14.19 Cr (+10% year on year). Net profit was ₹57.5 Lakh (4% margin). EBITDA was ₹1.04 Cr (7% margin). Revenue has grown at a compounded annual rate of +14% over three years and +8% over five years.
- ₹14.19 CrRevenue · FY 2025 · +10% YoY
- ₹57.5 LakhNet profit · 4% margin
- ₹1.04 CrEBITDA · 7% margin
- ₹10 LakhPaid-up capital
- 57Employees (provident fund records)
- +14%Revenue CAGR, 3 years
- +8%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Bios Lab Private Limited are on its company page.
Detailed financial statements for BiosLab
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to BiosLab
10 companies that operate in the same segment as BiosLab (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BiosLab
BiosLab is headquartered in India.
BiosLab has 57 employees.
The primary company behind BiosLab, Bios Lab Private Limited, reported revenue of ₹14.19 Cr for FY 2025, up 10% year on year.
BiosLab was established in 2008 and has grown from offering two products to more than 100 world-class healthcare items. Products are manufactured with state-of-the-art facilities and undergo rigorous analytical procedures at every stage to ensure high quality and desired pharmacological effects. The company is committed to producing economically viable pharmaceuticals for all societal segments and innovating solutions for challenging ailments. Research and development efforts are prioritized to maintain dedication to global benchmarks in the pharmaceutical field, while expanding horizons through perseverance and discipline.
BiosLab offers BIOTENLY ® Teneligliptin and TELEXA ® Telmisartan.
BiosLab operates through Bios Lab Private Limited.
The legal entities of BiosLab currently have 3 directors, including Sachin Navnitbhai Shishangiya, Bharat Ramjibhai Solanki, Sandip Navnitbhai Shishangia.